ArticleFrontiers in medicine2025
Global trends in typhoid and paratyphoid, and invasive non-typhoidal
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella.Nature communications · 2026Article
- Salmonellosis Among Children Aged 0-14 Years in Greece over the Period 2005-2024: Descriptive Analysis of Surveillance Data from the Mandatory Notification System.Microorganisms · 2026Article
- A novel green synthesized ZnO-based antimicrobial nanocomposite: synergistic action, in vitro cytotoxicity, and molecular docking studies of ceftazidime, metformin, and chitosan against multidrug-resistant Salmonella enterica.Microbial cell factories · 2026Article
- Antibiotic Resistance Trends and Prescribing Patterns in Pediatric Non-TyphoidalInfection and drug resistance · 2026Article
- Persistence of non-typhoidalFrontiers in microbiology · 2026Review
- Laboratory epidemiology ofOne health (Amsterdam, Netherlands) · 2025Article
- A nationwide cross-sectional study of antimicrobial resistance in Palestinian hospitals: insights from 10,000 clinical isolates.Antimicrobial resistance and infection control · 2025Article
- The Salmonella phage shock protein system is required for defense against host antimicrobial peptides.PLoS pathogens · 2025Article
- The burden and risk factors of chronic obstructive pulmonary disease in Asia and its countries from 1990 to 2021: a systematic analysis based on the 2021 global burden of disease study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the global burden of typhoid and paratyphoid fever, and Invasive Non-typhoidal Methods: Data were sourced from the Global Burden of Disease Study (GBD) 2021, focusing on age-standardized incidence rate (ASIR), mortality rate (ASMR), disability-adjusted life years rate (ASDR), and annualized percent change (EAPC). Results: From 1990 to 2021, the global burden of typhoid and paratyphoid fever decreased (EAPC = -4.15; 95% CI: -4.45 to -3.85). In contrast, the burden of iNTS showed a slow increasing trend (EAPC = 0.45; 95% CI: -0.32 to 1.22). The major epidemic trends were concentrated in regions with low and middle Socio-demographic Index (SDI). In high SDI regions, the age group most affected by deaths was 75 years and older, whereas in low SDI regions, particularly for typhoid and paratyphoid fever, deaths were more prevalent among children aged 0-14 years. Disability-adjusted life years (DALYs) and deaths due to multidrug-resistant Conclusion: While the global burden of typhoid and paratyphoid fever has declined, the burden of iNTS continues to rise slowly. The growing antimicrobial resistance of Salmonella further exacerbates the global disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.